Login / Signup

Estimating the false discovery risk of (randomized) clinical trials in medical journals based on published p-values.

Ulrich SchimmackFrantišek Bartoš
Published in: PloS one (2023)
The influential claim that most published results are false raised concerns about the trustworthiness and integrity of science. Since then, there have been numerous attempts to examine the rate of false-positive results that have failed to settle this question empirically. Here we propose a new way to estimate the false positive risk and apply the method to the results of (randomized) clinical trials in top medical journals. Contrary to claims that most published results are false, we find that the traditional significance criterion of α = .05 produces a false positive risk of 13%. Adjusting α to.01 lowers the false positive risk to less than 5%. However, our method does provide clear evidence of publication bias that leads to inflated effect size estimates. These results provide a solid empirical foundation for evaluations of the trustworthiness of medical research.
Keyphrases
  • healthcare
  • meta analyses
  • public health
  • small molecule
  • randomized controlled trial
  • systematic review
  • double blind
  • single cell